Barclays Forecasts Strong Price Appreciation for DexCom (NASDAQ:DXCM) Stock

DexCom (NASDAQ:DXCM - Get Free Report) had its price objective upped by stock analysts at Barclays from $90.00 to $93.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an "equal weight" rating on the medical device company's stock. Barclays's price objective would suggest a potential upside of 11.57% from the stock's current price.

Several other equities research analysts also recently issued reports on DXCM. Robert W. Baird reduced their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and raised their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Mizuho initiated coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Finally, Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $98.11.

DexCom Trading Up 2.2 %

Shares of NASDAQ:DXCM traded up $1.82 during midday trading on Monday, reaching $83.35. The company had a trading volume of 3,944,543 shares, compared to its average volume of 4,294,293. The company has a fifty day simple moving average of $71.05 and a two-hundred day simple moving average of $77.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $32.68 billion, a price-to-earnings ratio of 58.29, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. DexCom has a 1-year low of $57.52 and a 1-year high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The company's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Research analysts predict that DexCom will post 2.03 earnings per share for the current year.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,926 shares of company stock valued at $4,734,384. Corporate insiders own 0.32% of the company's stock.

Institutional Trading of DexCom

Large investors have recently made changes to their positions in the business. Versant Capital Management Inc bought a new position in shares of DexCom in the fourth quarter worth about $25,000. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Golden State Wealth Management LLC raised its position in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Optiver Holding B.V. bought a new position in DexCom in the 4th quarter valued at $33,000. Finally, TD Private Client Wealth LLC increased its stake in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares during the period. Institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.